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Abstract objective To assess progress in improving use of medicines in developing and transitional countries
by reviewing empirical evidence, 1990–2009, concerning patterns of primary care medicine use and
intervention effects.
methods We extracted data on medicines use, study setting, methodology and interventions from
published and unpublished studies on primary care medicine use. We calculated the medians of six
medicines use indicators by study year, country income level, geographic region, facility ownership
and prescriber type. To estimate intervention impacts, we calculated greatest positive (GES) and
median effect sizes (MES) from studies meeting accepted design criteria.
results Our review comprises 900 studies conducted in 104 countries, reporting data on 1033
study groups from public (62%), and private (mostly for profit) facilities (26%), and households. The
proportion of treatment according to standard treatment guidelines was 40% in public and <30% in
private-for-profit sector facilities. Most indicators showed suboptimal use and little progress over
time: Average number of medicines prescribed per patient increased from 2.1 to 2.8 and the
percentage of patients receiving antibiotics from 45% to 54%. Of 405 (39%) studies reporting on
interventions, 110 (27%) used adequate study design and were further analysed. Multicomponent
interventions had larger effects than single component ones. Median GES was 40% for provider and
consumer education with supervision, 17% for provider education alone and 8% for distribution of
printed education materials alone. Median MES showed more modest improvements.
conclusions Inappropriate medicine use remains a serious global problem.
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Introduction
Clinically inappropriate and economically inefficient use
of medicines has been reported widely (Ferech et al.
2006; Gallagher et al. 2007; Garfield et al. 2009), with
a number of reviews of the effectiveness of interven-
tions to improve medicines use (Grol & Grimshaw
2003; Sketris et al. 2009; Holloway 2011) mostly in
industrialised nations. Information from developing and
transitional countries, where routine monitoring of
medicines use is often lacking (WHO 2002, 2010a), is
scarce and mostly in the form of small studies (ICIUM
2004, 2011) making it difficult to draw generalisable con-
clusions about patterns of medicines use. This gap limits
initiatives to improve medicines use in resource-poor set-
tings since in-depth understanding of the nature and scope
of problems and of intervention effectiveness is lacking.
WHO has long recognised the problem of inappropriate
medicines use in developing and transitional countries
(WHO 1985, 2007), estimating that more than half of all
medicines are prescribed inappropriately and that half of
prescribed medicines are taken improperly by patients
(WHO 2002; Sabate 2003). The International Network of
the Rational Use of Drugs (INRUD), with WHO, devel-
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oped a method and indicators to measure medicines use in
primary care facilities in resource-poor settings (WHO
1993). This method has been used for numerous descriptive
surveys and evaluations of interventions to improve use.
To assess progress on medicines use in low- and
middle-income countries over the last 20 years in a system-
atic way, WHO supported the creation of a database of
all studies of primary care medicines use in developing
and transitional countries reporting on any of a defined
set of medicines use indicators. Summary data for
1990–2006 from the database have been published
(WHO 2009). The objective of the current study was to
undertake a more in-depth analysis of studies over a
longer period of time from the updated WHO Medicines
Use Database for 1990–2009 on patterns of medicines
use and effects of interventions to improve medicines use
in developing and transitional countries.
Methods
Details of the creation of the WHO Medicines Use
Database and descriptive analyses have been presented
elsewhere (WHO 2009). Briefly, we systematically identified
studies published in the scientific literature or reported to
international and national organisations during
1990–2009 on quantitative medicines use data, using 19
WHO/INRUD indicators (WHO 1993) or 20 other
standard measures. Eligible studies reported data from a
primary care setting in a developing or transitional
country, defined as any country except those located in
North America or Western Europe, Australia, New Zealand
and Japan. Data on medicine use plus details of study setting
and methodology were extracted from the reports/articles
and entered into a Microsoft AccessTM database.
Search strategy
Studies were identified in the INRUD bibliography
(INRUD 2010) (containing 8717 references as of
2.6.2010 and identified from systematic searches in PUB-
MED, EMBASE and over 50 hand-searched journals), a
secondary PubMed search, and WHO and Management
Sciences for Health (MSH) archives. Search terms
included ‘drug use’, ‘drug utilisation’, ‘drug therapies’,
‘prescriptions’, ‘prescribing’, ‘antibiotics’, ‘diarrhoea’,
‘acute respiratory infections’, ‘malaria’, ‘interventions’,
‘evaluation studies’, ‘integrated management of childhood
illness’, ‘education’, ‘developing countries’, ‘Africa’, ‘Asia’
and ‘Central America and South/Latin America’. In addi-
tion, all studies presented at the first and second Interna-
tional Conferences on Improving the Use of Medicines
(ICIUM) held in 1997 and 2004 (ICIUM 1997, 2004),
respectively, were reviewed and included if a full report
was available from the authors. All identified studies
were read by the first two authors (KAH and VI) and
included in the database if both agreed on their eligibility
for entry. Any disagreements on eligibility were discussed
and resolved before inclusion.
Data entry
Data were extracted for each study population whose
medicines use practices were measured and entered into
the database in 102 explicitly defined fields, covering
setting (primary health care centre [PHC], hospital outpa-
tient department, pharmacy, household), sector (public/
private), prescriber type (doctor, nurse, paramedic, other)
and year of data collection (WHO 2009). Each record in
the database describes all medicines use indicators
reported for a specific study group measured at a particu-
lar point in time for a specific provider in a specific
setting. Data from multiple countries or multiple groups
(e.g. different facility types, sectors or prescriber types)
reported in a single study were entered into the database
as separate records. Data from multiple articles describ-
ing the same study results (i.e. medicines use in the same
facilities in a single time period) were entered as a single
record in the database (with up to three references cited). If
an article reported resulted from a mixed setting (e.g. more
than one prescriber or health facility type), only one record
was entered in the database – reflecting either a mix (e.g.
hospitals + PHCs) or the dominant (if over 80%) setting.
Interventions were classified according to the component
that best captured the nature of the intervention strategy
evaluated. While some interventions consisted of only one
component, many involved a mix of components; in these
cases, classification was done according to a defined set of
hierarchical rules. For example, ‘printed educational mate-
rial’ was classified as such, being a single component inter-
vention. Although ‘provider education’ often involved
printed materials, interventions in this category always
included an element of interaction between teacher and pro-
vider. Similarly, ‘provider supervision’ often involved an
educational component, but always included an element
of follow-up interaction with the provider. In other hier-
archical approaches, an essential medicines programme
always involved an element of drug supply and provider
education, while community case management always
involved elements of training and supervising community
members to treat illness in the community. All data were
entered (by VI) and checked (by KAH). The data were
exported into Microsoft ExcelTM for analysis. Frequency
distributions of key variables were created to assess data
entry accuracy prior to analysis.
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Analysis
All data from non-intervention studies and baseline data
from intervention studies were included in descriptive
analyses. Control group data from post-only intervention
studies and repeated measures from national surveys
reported with no discrete intervention were also included.
In this article, we present descriptive data on six com-
monly reported WHO/INRUD prescribing indicators:
average number of medicines prescribed per patient;
percentage of patients receiving an antibiotic; percentage
of patients receiving an injection; percentage of patients
treated in accordance with a standard treatment guideline
(STG); percentage of medicines prescribed from an essen-
tial medicines list (EML); and percentage of medicines
prescribed by generic name. These six WHO/INRUD
prescribing indicators were chosen because their measure-
ment is standardised (unlike many other indicators), and
the number of studies reporting these indicators in
surveys covering all age groups was much larger than
studies reporting other indicators. Prescribing indicators
used in the treatment of illness in children under 5 years
(e.g. integrated management of childhood illness) were
not included in this analysis.
Analyses of intervention impacts used data from studies
meeting commonly accepted criteria for valid study
designs – randomised controlled trials (RCT), pre–post
with control and time series studies. For studies reporting
multiple post-intervention assessments, only the last post-
intervention data point was used to calculate intervention
effects. Interventions were classified into 12 types by
dominant component, as described above and elsewhere
(WHO 2009). We included any of the 39 indicators from
the WHO Medicines Use Database in analyses of inter-
vention effects.
Due to the heterogeneity of the studies, a formal meta-
analysis was not possible. To estimate trends and patterns
of use, we calculated medians of specific medicine use
indicators across studies by survey year, geographic
region, sector, World Bank country income level or
prescriber type. Studies were only included if medicines
use was investigated in more than two facilities and/or
included more than 599 patient encounters. We con-
ducted sensitivity analyses by excluding certain categories
of data from descriptive analyses, such as data from post-
only studies or baseline data from the intervention groups
in intervention studies. Sensitivity analyses did not
substantially change the results, so all data are included
in the results presented.
We calculated the effect size of interventions with
strong study designs for each medicines use outcome
measure as follows (Ross-Degnan et al. 1997). For
percentage outcome measures (e.g. % patients receiving
antibiotics):
Effect size ¼ ð%Post%PreÞIntervention
 ð%Post%PreÞControl
For numeric outcome measures (e.g. average number of
drugs per patient):
Effect size ¼ ð½Post Pre=PreÞIntervention
 ð½Post Pre=PreÞControl
All outcome measures were converted to a scale where
a positive number indicated positive change. To indicate
the magnitude of the effect of an intervention, we used
two measures of overall effectiveness. The greatest effect
size (GES) corresponds to the single outcome measure
reported showing the greatest positive change towards
better medicines use. As one indicator may not
adequately reflect overall intervention impact, we also
calculated the median effect size (MES) corresponding to
the median change across all the reported indicators of
medicines use. To estimate the overall effectiveness of
different intervention types, we calculated the medians of
the GES and MES measures across all studies by
intervention type.
Results
We identified 900 studies with 1033 study groups report-
ing data on primary care practice in 104 countries. Of
these study groups, 901 (87%) involved three or more
health facilities and/or 600 or more patient encounters;
only these study groups were included in descriptive
analyses. A total of 325 (36%) study groups included
only children under 5 years, while the remainder included
individuals over 5 years or all ages. The majority (62%)
of studies reported practices in the public sector, 24% in
the private-for-profit sector, 2% in the private-not-
for-profit sector and the rest in households or unknown
facility types. While by definition all studies reported
ambulatory primary health care (PHC) practices, 46%
were conducted in PHC settings, 21% in a mix of
hospitals and PHC settings, 13% in hospitals only, 15%
in pharmacies, 2% in non-licensed shops and 3% in
households. Prescribers were doctors in 35% of studies,
nurses or paramedics in 52%, community health workers
in 6%, pharmacy personnel in 4% and lay providers in
3% of studies.
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Patterns of medicine use
Figure 1 shows medicines use during 1990–2009 for six
INRUD/WHO prescribing indicators and mainly reflects
medicines use in the public sector as few surveys in the
private sector have reported these measures. Overall, the
values of these indicators have not changed substantially
over the last 20 years. The median number of medicines
prescribed per patient has increased steadily, from 2.1
before 1992 to 2.8 in 2007–2009. Of concern, the
median percentage of patients in primary care receiving
antibiotics has continued to increase over time from 42%
pre-1992 to 51% in 2007–2009, while the median
percentage of patients receiving injections remains around
20%. Despite small increases over time, only 50% of
treatment followed STGs at the end of the study period.
Table 1 shows the values of the six prescribing indica-
tors by geographic region, sector, country income level
and prescriber type, aggregating all studies over time.
Results are generally similar across geographic regions,
with some exceptions. The average number of medicines
prescribed and percentage injection use tends to be some-
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Figure 1 Median values of medicines use indicators over time.
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what higher in the Africa, Eastern Mediterranean and
Western Pacific regions. Prescribing of medicines from an
EML and by generic name is less common in the Euro-
pean region.
Except for antibiotic prescribing, medicine use in the
public sector tends to be closer to recommended practices
than in the private-for-profit sector, as reflected by more
use of EML drugs, more frequent prescribing by generic
name, and greater compliance with STGs. This difference
is still seen when the analysis is restricted to doctors,
nurses and paramedical workers (i.e. excluding all infor-
mal prescribers in the private sector). The number of
studies in the private-not-for-profit sector is very small,
which precludes accurate comparison with other settings.
While fewer than 50% of prescriptions are in accor-
dance with STGs in countries at all income levels, upper-
middle-income countries tend to prescribe fewer EML
medicines, fewer injections and less frequently by generic
name. Nurses and paramedics tend to prescribe more
EML medicines and more frequently by generic name
than doctors, but otherwise, their prescribing patterns are
similar.
Effects of interventions
A total of 405 studies reported on an intervention to
improve medicine use. Of these, only 110 (27%)
interventions were evaluated using methodologically
adequate study designs. Overall, the median GES was
19% and the median MES 7%.
Most interventions involved a mix of educational and
managerial components. Only economic interventions,
which targeted providers or patients, tended not to
incorporate a mix of components. Almost all educational
interventions included printed materials and almost all
supervisory interventions included some form of provider
or consumer education. Community case management
interventions consisted largely of community members
being provided with medicines and trained and super-
vised to deliver basic primary care in the community.
Essential drug programmes involved elements of provider
education and supervision with a controlled drug supply.
Provider group process strategies were interventions that
involved providers in a quality improvement process,
such as peer review or self-monitoring of prescription
behaviour. Figure 2 shows (a) the GES for each interven-
tion study and the median GES by intervention type and
(b) the MES for each intervention study and the median
MES by intervention type.
Most interventions included either provider education,
provider supervision or both. Fewer targeted consumer or
patient education. The median effectiveness of interven-
tions varied widely, with examples of large GES and MES
as well as examples with no effects in most categories.
Table 1 Median INRUD medicines use indicators across studies, by geographic region, sector, country income level and prescriber
type
Sample size
of study
groups
Average number
of medicines
per patient
% patients
receiving
antibiotics.
% patients
receiving
injections
% prescribed
medicines on
an EML
% medicines
prescribed by
generic name
% patients
treated according
to STGs
WHO geographic region
Latin America 14–34 1.9 (34) 37.0 (29) 13.2 (14) 71.4 (16) 67.3 (14) 39.2 (29)
Europe 3–21 2.1 (21) 40.9 (14) 18.7 (10) 59.0 (3) 38.3 (9) 38.9 (5)
Africa 95–184 2.6 (184) 45.9 (172) 28.4 (155) 89.0 (95) 65.1 (116) 40.3 (133)
Eastern Mediterranean 13–57 2.7 (54) 53.6 (57) 27.1 (49) 90.8 (13) 57.1 (24) 34.9 (25)
South East Asia 45–124 2.4 (124) 47.9 (124) 9.7 (72) 77.0 (49) 44.7 (48) 31.2 (45)
Western Pacific 16–38 2.8 (35) 50.8 (38) 27.1 (30) 75.5 (22) 66.5 (16) 35.0 (18)
Sector – all prescribers
Private-not-for-profit 5–16 3.1 (16) 43.4 (14) 37.0 (11) 78.4 (9) 62.5 (10) 18.7 (5)
Private-for-profit 27–75 2.4 (75) 43.8 (69) 20.0 (43) 53.0 (27) 20.0 (29) 5.5 (30)
Public 140–313 2.4 (313) 49.0 (311) 20.0 (235) 88.2 (140) 61.8 (162) 40.1 (180)
World Bank country income level
Low 91–216 2.3 (202) 48.2 (184) 24.0 (166) 88.0 (87) 71.5 (101) 35.0 (145)
Lower-middle 81–207 2.8 (173) 50.0 (188) 21.7 (127) 81.7 (84) 49.0 (91) 35.7 (75)
Upper-middle and high 17–85 2.3 (77) 40.4 (62) 12.0 (37) 61.1 (27) 42.8 (35) 39.2 (35)
Prescriber type
Doctor 47–178 2.6 (178) 51.0 (162) 21.0 (109) 73.9 (69) 44.8 (88) 33.3 (47)
Nurse/paramedic 111–236 2.4 (236) 48.0 (231) 22.5 (196) 88.2 (111) 67.0 (127) 38.5 (172)
Individual sample sizes in parentheses.
EML, essential medicines list; INRUD, International Network of the Rational Use of Drugs; STG, standard treatment guideline.
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One of the commonest interventions, provider educa-
tion alone, had relatively small effect (median
GES = 18%, MES = 6%). The greatest median effects
were observed for multicomponent interventions such as
those incorporating provider and consumer education
with supervision (median GES = 40%, MES = 27%) or
without supervision (median GES = 20%, MES = 13%),
or those involving provider and community education,
Greatest Positive Effect Sizes (GES) of Interventions on Medicines Use
–40 –20 0 20 40 60 80 100
Greatest positive indicator change Median of greatest positive indicator change
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Economic Strategy
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Community Case Management
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Median Effect Sizes of Interventions (MES) on Medicines Use
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Consumer Education
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Figure 2 Effect sizes of interventions on medicines use.
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supervision and a controlled drug supply, such as com-
munity case management (median GES = 33%,
MES = 32%). By contrast, single component interven-
tions such as printed educational materials alone (median
GES = 8%, MES = 1%) or poorly focused interventions
such as national policies (median GES = 17%,
MES = 10%) or economic strategies (median
GES = 13%, MES = 1%) tended to have a smaller or
no positive impact.
Discussion
Results from 900 studies reported over two decades show
continual suboptimal prescribing in primary care in all
regions of the world. Less than half of all patients are
treated in accordance with STGs. This finding confirms
what has been reported previously (WHO 2002, 2009).
The 25th – 75th percentile range for each indicator
shows that there has been little change in the distribution
of results for these indicators over time and that medicine
use has not improved in the most recent period
2007–2009 (not reported in our previous summary
analysis [WHO 2009]). As more than 80% of studies
examined medicines use in primary care facilities and
hospitals, the data mainly reflect the practices of doctors,
nurses and paramedical staff in those settings. Poor
compliance with STGs may be partly explained by persistent
increases over time in antibiotic prescribing and failure to
reduce use of injections, both of which are inappropriate
practices for many primary care patients.
Prescribing in the private-for-profit sector tended to be
worse than in the public sector, as indicated by poorer
compliance with STGs and lower use of EML and generic
drugs. While some of the poorer prescribing observed in
the private sector may be due to the lack of qualification
of informal prescribers, the data indicate that the
prescribing by doctors, nurses and paramedical staff is
also worse in the private sector. Poorer prescribing in the
private sector has been noted in individual studies (Trap
et al. 2002; Trap & Hansen 2002; Park et al. 2005).
This situation is of serious concern because a large pro-
portion of health care is provided by private and informal
sector practitioners in many low- and middle-income
countries (WHO 2010b). Determinants of private sector
prescribing are poorly studied and require more
attention.
Interestingly, use of EML medicines and prescribing by
generic name was lower in upper-middle and higher-
income countries. This may indicate greater access to
medicines not included on EML due to higher incomes or
broader insurance coverage. There is a need for detailed
studies on the clinical appropriateness and cost-effectiveness
of medicines use in these settings. Adherence to STGs
remains poor across all country income groups.
Nurses and paramedical workers appear to prescribe
more in accordance with recommended practices than
doctors, with more prescribing of EML drugs and medi-
cines by generic name, and greater adherence to STGs.
Few studies have reported appropriateness of prescribing
by different provider types, although nurses have been
shown to prescribe as well as doctors in some settings
(Massele & Mwaluko 1994; Ministry of Health Ethiopia
2003; Asrar Ali & Jaffer 2005). Our results suggest that
policies in many countries that allow nurses to prescribe
in primary care may be justified.
The 405 studies evaluating interventions to improve
medicines use in developing and transitional countries are
relatively few for a 20-year period and, worryingly, only
27% used adequate study designs. Thus, evidence on
interventions to improve use is based on only 110 studies.
Other reviews of health worker interventions have noted
the lack of adequate study designs in evaluating interven-
tion effectiveness (Rowe et al. 2005). As reported in
reviews of interventions from industrialised countries
(Grol & Grimshaw 2003; Sketris et al. 2009), we found
that most interventions were educational and that the
average median intervention effect size was small – only
about 12% improvement in prescribing. The median
greatest reported effect was 19% – higher than in most
other reviews. This may reflect poorer baseline adherence
to desired prescribing practices or poorer health infra-
structure in developing than developed countries
(Jamtvedt et al. 2006). Multi-component interventions
were clearly more effective than single component ones,
printed educational materials having very little effect and
provider education alone modest impact. Similar findings
have been reported in reviews from industrialised coun-
tries (Wensing et al. 1998; Siddiqi et al. 2005; Francke
et al. 2008; Sketris et al. 2009).
Effectiveness of interventions will be affected by the
quality of intervention materials and approaches and
how well interventions are implemented. Unfortunately,
these factors are difficult to investigate as few authors
describe details of the intervention setting and compo-
nents or the fidelity of implementation. Future studies
need to describe medicines use interventions in detail,
ideally following a structured reporting template, in
which classification of multicomponent interventions is
standardised and where some key indicators of the quality
and completeness of intervention implementation are
reported. The GES indicator, which reflects the greatest
positive change in one targeted outcome, may not
adequately reflect the overall impact of an intervention; the
MES across all targeted indicators may more accurately
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reflect the achievable or expected magnitude of effects of
interventions in practice.
Ours is the first review of longitudinal patterns of
medicines use and of the effectiveness of interventions to
improve medicines use in developing and transitional
countries. In the absence of other medicines use monitor-
ing systems, this summary analysis of systematically com-
piled studies can provide information on global progress
in improving use of medicines, particularly in the public
sector. While summary data for 1990–2006 were
reported previously by WHO, this more detailed analysis
covers more recent studies and serves to strengthen the
evidence showing serious and continued inappropriate
use of medicines. Many more studies are needed in the
private and informal sectors, which provide much health
care in developing countries.
Our review has many limitations. Much work on
improving medicines use in developing and transitional
countries is never published, being carried out as part of
operational programmes. We limited our review to
primary care studies, as there are no standardised drug use
indicators for hospital or specialty care. As the studies
done in different countries were heterogeneous, involving
different target outcomes, settings, sample sizes and
methods, we were unable to undertake a formal meta-
analysis of intervention effects. We also lacked the data
to estimate the descriptive indicators of medicines use
with any specified precision, especially because sample
sizes were relatively small when the data were disaggre-
gated by time period, region, sector or provider type.
However, the overall stability of median results over time
and across groups suggests that the descriptive data may
have reasonable validity.
Although we extended considerable effort to identify
studies for the review, it is likely that we missed many
unpublished reports at country level. We also made great
effort to abstract data from articles and reports
accurately and consistently. However, studies were often
poorly described and/or had missing data that may have
resulted in some misclassification, particularly with
regard to study setting and intervention type. Some
countries had undertaken many more studies than others
but we made no attempt to adjust for this fact. In addi-
tion, some studies were considerably larger than others.
We did not weight results by study size; instead each
study group reported was treated as a single data point
with equal weight without regard to sample size or
variance. We did not attempt to estimate statistical differ-
ences between groups, as variance would be greatly
underestimated. However, sensitivity analyses that
excluded certain groups did not substantially change the
results.
In conclusion, this is the first major review of progress
in primary care medicines use in developing and transi-
tional countries. Overall medicines use remains poor in
all regions, in both the public and private sectors. Given
the small number of well-designed intervention studies,
there is an urgent need to test multicomponent interven-
tions to improve medicines use and to evaluate
adequately the impact of broader national programs.
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